Selinexor in combination with venetoclax and decitabine in patients with refractory myelodysplastic syndrome previously exposed to hypomethylating agents: three case reports

Selinexor in combination with venetoclax and decitabine in patients with refractory myelodysplastic syndrome previously exposed to hypomethylating agents: three case reports

The management of patients with myelodysplastic syndrome (MDS) refractory to hypomethylating agents (HMAs) remains a challenge with few reliably effective treatments. Preclinical studies have shown that the inhibition of the nuclear export protein XPO1 causes nuclear accumulation of p53 and disrupti...

Full description

Saved in:
Bibliographic Details
Main Authors: Yunshuo Xiao, Kun Yang, Qiuying Huang, Changqing Wei, Manlv Wei, Zhili Geng, Hui Wu, Tianhong Zhou, Xialoin Yin, Yali Zhou
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Oncology
Subjects:
selinexor
venetoclax
hypomethylating agents
myelodysplastic syndrome
acute myeloid leukemia
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1477697/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1477697/full

Similar Items